Cervical mucinous adenocarcinoma, minimal deviation variant

Summary

Cervical mucinous adenocarcinoma, minimal deviation variant (MONDO:0006140) is a disease. A subtype of cervical mucinous adenocarcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	cervical mucinous adenocarcinoma, minimal deviation variant
Mondo ID	MONDO:0006140
EFO	EFO:1000169
DOID	DOID:6627
NCIT	C40206
UMLS	C1516423
MedGen	273125
GARD	0024307
Is cancer (heuristic)	no

Also known as: cervical adenoma malignum · cervical mucinous adenocarcinoma, minimal deviation type · cervical mucinous adenocarcinoma, minimal deviation variant

Data availability: 1 cell line.

Disease family

This is a subtype of cervical mucinous adenocarcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › adenocarcinoma › mucinous adenocarcinoma › cervical mucinous adenocarcinoma › cervical mucinous adenocarcinoma, minimal deviation variant

Related subtypes (5): uterine ligament mucinous adenocarcinoma, signet ring cell variant cervical mucinous adenocarcinoma, intestinal variant cervical mucinous adenocarcinoma, endocervical type cervical mucinous adenocarcinoma, cervical villoglandular adenocarcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.